Johnson Matthey (OTCMKTS:JMPLY – Get Rating) has been assigned an average recommendation of “Hold” from the twelve research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $2,404.00.
A number of research analysts have commented on the company. Panmure Gordon raised Johnson Matthey from a “sell” rating to a “hold” rating in a report on Tuesday, January 18th. Jefferies Financial Group upgraded Johnson Matthey from a “hold” rating to a “buy” rating in a research report on Wednesday, May 4th. UBS Group cut their target price on Johnson Matthey from GBX 1,875 ($23.42) to GBX 1,800 ($22.49) in a research report on Monday, April 4th. Zacks Investment Research downgraded Johnson Matthey from a “buy” rating to a “hold” rating in a research report on Tuesday, February 15th. Finally, Barclays cut their target price on Johnson Matthey from GBX 2,510 ($31.36) to GBX 2,320 ($28.98) and set an “underweight” rating for the company in a research report on Friday, January 14th.
Shares of OTCMKTS JMPLY opened at $57.30 on Monday. The company has a quick ratio of 0.78, a current ratio of 1.34 and a debt-to-equity ratio of 0.39. The stock’s fifty day moving average price is $50.69 and its two-hundred day moving average price is $54.83. Johnson Matthey has a one year low of $45.72 and a one year high of $93.23.
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers’ products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet’s natural resources.
- Get a free copy of the StockNews.com research report on Johnson Matthey (JMPLY)
- Mattel Stock is Ready to Catch
- Littelfuse Stock is Hitting on All Cylinders
- HCA Healthcare Stock is Ready to Climb Higher
- ChemoCentryx: A Biotech Stock Well Worth the Risk
- Skechers Stock Can Be Bought on Pullbacks
Receive News & Ratings for Johnson Matthey Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson Matthey and related companies with MarketBeat.com's FREE daily email newsletter.